Evidence map›Paper›PMID 42694732›Full record

ArticleThe Lancet regional health. Western Pacific2026

Treatment utilisation for Aboriginal and Torres Strait Islander people diagnosed with prostate cancer in Australia: a population-based study.

Mei Ling Yap, Gabriel Gabriel, Joseph Descallar, Susan Anderson, Geoff P Delaney, Viet Do, Rebecca Murray, Karen Wong, Henry H Woo, Kalinda Griffiths and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mei Ling YapThe Cancer Program, The George Institute for Global Health, UNSW Sydney, Randwick, NSW, Australia.
Gabriel GabrielSouth-Western Sydney Clinical Campus, School of Clinical Medicine, UNSW Sydney, Liverpool, NSW, Australia.
Joseph DescallarSouth-Western Sydney Clinical Campus, School of Clinical Medicine, UNSW Sydney, Liverpool, NSW, Australia.
Susan AndersonAboriginal Consumer, Sydney, NSW, Australia.
Geoff P DelaneyThe Cancer Program, The George Institute for Global Health, UNSW Sydney, Randwick, NSW, Australia.
Viet DoLiverpool and Macarthur Cancer Therapy Centres, Liverpool, NSW, Australia.
Rebecca MurrayLiverpool and Macarthur Cancer Therapy Centres, Liverpool, NSW, Australia.
Karen WongLiverpool and Macarthur Cancer Therapy Centres, Liverpool, NSW, Australia.
Henry H WooDepartment of Urology, Blacktown & Mt Druitt Hospitals, Blacktown, NSW, Australia.
Kalinda GriffithsPoche SA+NT, College of Medicine and Public Health, Flinders University, SA, Australia.
Keziah Bennett-BrookGuunu-maana (Heal) Aboriginal & Torres Strait Islander Health Program, The George Institute for Global Health, Randwick, NSW, Australia.
Julieann CoombesGuunu-maana (Heal) Aboriginal & Torres Strait Islander Health Program, The George Institute for Global Health, Randwick, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Prostate cancer is the most common cancer diagnosed in Aboriginal and Torres Strait Islander men. Surgery and radiotherapy are curative options, with equivalent survival but different side effects and financial costs. We aim to determine the uptake of surgery and/or radiotherapy for prostate cancer by Aboriginal and Torres Strait Islander people within New South Wales (NSW). Methods: This was an individualised patient linked-data study which used the NSW Cancer Registry (2009-2018), NSW Admitted Patient Data Collection, Outpatient Radiation Oncology Data and Register of Births, Deaths and Marriages. Fine-Gray Competing Risk models were used to estimate cause-specific hazards for time to radiotherapy and time to prostatectomy with a competing risk of death. Findings: There were 59,621 people diagnosed with prostate cancer; 1061 (1.8%) were Aboriginal and Torres Strait Islander people. The median follow-up time was 6.3 years. A total of 22,946 (41.4%) patients received a prostatectomy; in Aboriginal and Torres Strait Islander people, it was lower at 362 (36.6%) patients. A total of 17,196 (31.0%) received external beam radiation therapy and for Aboriginal and Torres Strait Islander people, 349 (35.3%) received radiotherapy. In univariate analysis, Aboriginal and Torres Strait Islander people were less likely to receive a radical prostatectomy (HR 0.9, p < 0.05) than the rest of the population. However this association was lost when adjusting for possession of private insurance and comorbidities. Aboriginal and Torres Strait Islander people were more likely to receive radiotherapy on multivariable analysis (HR 1.2, p = 0.001). Interpretation: Aboriginal and Torres Strait Islander people are more likely to receive radiotherapy but less likely to receive surgery than the rest of the NSW population, with socio-economic factors associated with the treatment received. It is imperative there is equitable and affordable access to treatment options for Aboriginal and Torres Strait Islander people. Funding: This study was funded by the 2023 UNSW Health Systems Theme Collaborative grant.

Indexed as

Aboriginal and Torres Strait Islander peopleFirst NationsHealth disparitiesHealth equityPatterns of careProstate cancer

Identifiers

PMID42694732
PMCPMC13540680

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.